NCT07413133

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

A Phase 1 Pharmacokinetic Study in Healthy Adult Volunteers to Evaluate the Bioavailability of ABBV-8736 Following Subcutaneous Administration Relative to Intravenous Administration

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	ABBV-8736	Intravenous Injection
DRUG	ABBV-8736	Subcutaneous Injection

Timeline

• Start date: 2026-02-11
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2026-02-17
• Last updated: 2026-03-04

Locations

2 sites across 1 country: United States